Novel techniques for the treatment of localized prostate cancer: Evidence of efficacy?

Current Urology Reports

Volumn 8, Issue 3, 2007, Pages 203-210

  Robinson, Marnie R ^b   Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FINASTERIDE; GONADORELIN; PLACEBO; STEROID 5ALPHA REDUCTASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CRYOABLATION; CRYOTHERAPY; DIET; DIET SUPPLEMENTATION; DRUG MECHANISM; GYNECOMASTIA; HIGH INTENSITY FOCUSED ULTRASOUND; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; MONOTHERAPY; MORTALITY; NONHUMAN; POTENCY DISORDER; PROSTATE CANCER; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ROBOTICS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; MALE; PROSTATE TUMOR; REVIEW; UROLOGY;

HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UROLOGY;

EID: 34248563041     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-007-0007-7     Document Type: Article

References (62)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Farkas A, Schneider D, Perrotti M, et al.: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998, 52:444-448.
3. Stephenson RA: Prostate cancer trends in the era of pros-tate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002, 29:173-181.
4. • Mouraviev V, Polascik TJ: Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol 2006, 16:152-156. This review article highlights current trends in cryosurgery for prostate cancer.
5. Grubb RL III, Vardi IY, Bhayani SB, Kibel AS: Minimally invasive approaches to localized prostate cancer. Hematol Oncol Clin North Am 2006, 20:879-895.
6. Onik G, Narayan P, Vaughan D, et al.: Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology 2002, 60:109-114.
7. Janzen NK, Han K-R, Perry KT, et al.: Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. J Endourol 2005, 19:520-525.
8. Djavan B, Susani M, Bursa B, et al.: Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 1999, 5:139-142.
9. Polascik TJ, Mouraviev V, Sun L, et al.: Prostate cancer laterality as a rationale for the clinical application of focal ablative therapy: an analysis of 1184 prostatectomy specimens. Seventh Annual Surgical Urologic Oncology meeting to discuss current topics and strategies [abstract]. Urol Oncol 2006:92.
10. Masson P, Prepelica KL, Lambert EH, et al.: Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. J Urol 2005, 173:179.
11. Beerlage HP, van Leenders GJ, Oosterhof GO, et al.: High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate 1999, 39:41-46.
12. Blana A, Walter B, Rogenhofer S, Wieland WF: High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004, 63:297-300.
13. Thuroff S, Chaussy C, Vallancien G, et al.: High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European Multicentric Study. J Endourol 2003, 17:673-677.
14. Chaussy C, Thuroff S: The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003, 4:248-252.
15. Vallancien G, Prapotnich D, Cathelineau X, et al.: Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 2004, 171:2265-2267.
16. Poissonnier L, Chapelon J-Y, Rouviere O, et al.: Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007, 51:381-387.
17. Lee HM, Hong JH, Choi HY: High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:439-443.
18. Uchida T, Ohkusa H, Nagata Y, et al.: Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006, 97:56-61.
19. Menon M, Tewari A, Baize B, et al.: Prospective comparison of radical retropubic prostatectomy and robot-assisted anatomic prostatectomy: the Vattikuti Urology Institute experience. Urology 2002, 60:864-868.
20. Tewari A, Srivasatava A, Menon M: A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int 2003, 92:205-210.
21. Ahlering TE, Woo D, Eichel L, et al.: Robot-assisted versus open radical prostatectomy: a comparison of one surgeon's outcomes. Urology 2004, 63:819-822.
22. Ball AJ, Gambill B, Fabrizio MD, et al.: Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution. J Endourol 2006, 20:723-731.
23. Menon M, Tewari A: Robotic radical prostatectomy and the Vattikuti Urology Institute technique: an interim analysis of results and technical points. Urology 2003, 61:15-20.
24. Kaul S, Savera A, Badani K, et al.: Functional outcomes and oncological efficacy of Vattikuti Institute prostatectomy with Veil of Aphrodite nerve-sparing: an analysis of 154 consecutive patients. BJU Int 2006, 97:467-472.
25. Walsh PC, Marschke P, Ricker D, Burnett AL: Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000, 55:58-61.
26. Litwin MS, Melmed GY, Nakazon T: Life after radical prostatectomy: a longitudinal study. J Urol 2001, 166:587-592.
27. Guazzoni G, Cestari A, Naspro R, et al.: Intra- and peri-operative outcomes comparing radical retropubic and laparoscopic radical prostatectomy: results from a prospective, randomised, single-surgeon study. Eur Urol 2006, 50:98-104.
28. Ghavamian R, Knoll A, Boczko J, Melman A: Comparison of operative and functional outcomes of laparoscopic radical prostatectomy and radical retropubic prostatectomy: single surgeon experience. Urology 2006, 67:1241-1246.
29. Bentas W, Wolfram M, Jones J, et al.: Robotic technology and the translation of open radical prostatectomy to laparoscopy: the early Frankfurt experience with robotic radical prostatectomy and one year follow-up. Eur Urol 2003, 44:175-181.
30. Patel VR, Tully AS, Holmes R, Lindsay J: Robotic radical prostatectomy in the community setting: the learning curve and beyond: initial 200 cases. J Urol 2005, 174:269-272.
31. Webster TM, Herrell SD, Chang SS, et al.: Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol 2005, 174:912-914.
32. Freedland SJ, Aronson WJ: Obesity and prostate cancer. Urology 2005, 65:433-439.
33. •• Rodriguez C, Freedland SJ, Deka A, et al.: Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:63-69. This large, longitudinal study examined the relationship of body mass index and weight change in relation to incidental prostate cancer by disease stage and grade at diagnosis.
34. • Ornish D, Weidner G, Fair WR, et al.: Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005, 174:1065-1070. This study describes how an intensive diet and lifestyle modification can affect PSA, treatment trends, and serum-stimulated LNCaP cell growth in men with biopsy-proven prostate cancer.
35. Mavropoulos JC, Isaacs WB, Pizzo SV, Freedland SJ: Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer? Urology 2006, 68:15-18.
36. Yancy WS Jr, Olsen MK, Guyton JR, et al.: A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004, 140:769-777.
37. Meckling KA, O'Sullivan C, Saari D: Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. J Clin Endocrinol Metab 2004, 89:2717-2723.
38. Boileau TWM, Liao Z, Kim S, et al.: Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003, 95:1578-1586.
39. Nebeling LC, Miraldi F, Shurin SB, Lerner E: Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 1995, 14:202-208.
40. Pantuck AJ, Leppert JT, Zomorodian N, et al.: Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006, 12:4018-4026.
41. Freedland SJ, Humphreys EB, Mangold LA, et al.: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294:433-439.
42. Demark-Wahnefried W, Price DT, Polascik TJ, et al.: Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 2001, 58:47-52.
43. Schuurman AG, van den Brandt PA, Dorant E, et al.: Association of energy and fat intake with prostate carcinoma risk. Cancer 1999, 86:1019-1027.
44. Gann PH, Hennekens CH, Sacks FM, et al.: Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994, 86:281-286.
45. Morton MS, Chan PSF, Cheng C, et al.: Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997, 32:122-128.
46. Lin X, Gingrich JR, Bao W, et al.: Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. Urology 2002, 60:919-924.
47. Demark-Wahnefried W, Robertson CN, Walther PJ, et al.: Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004, 63:900-904.
48. Chodak GW, Keane T, Klotz L: Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002, 60:201-208.
49. Kawakami J, Cowan JE, Elkin EP, et al.: Androgen-deprivation therapy as primary treatment for localized prostate cancer. Cancer 2006, 106:1708-1714.
50. Ueno S, Namiki M, Fukagai T, et al.: Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006, 13:1494-1500.
51. Labrie F, Candas B, Gomez J-L, Cusan L: Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002, 60:115-119.
52. See WA, Wirth MP, McLeod DG, et al.: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. J Urol 2002, 168:429-435.
53. Wirth MP, See WA, McLeod DG, et al.: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the Early Prostate Cancer Program at median followup of 5.4 years. J Urol 2004, 172:1865-1870.
54. Iversen P, Johansson J-E, Lodding P, et al.: Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Study Group Study Number 6. J Urol 2004, 172:1871-1876.
55. • McLeod DG, Iversen P, See WA, et al.: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006, 97:247-254. This is the 7.4-year follow-up of the Early Prostate Cancer trial of bicalutamide (150-mg) monotherapy.
56. Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
57. Bostwick DG, Qian J, Civantos F, et al.: Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004, 2:228-235.
58. Leibowitz RL, Tucker SJ: Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 2001, 6:177-182.
59. Scholz MC, Jennrich RI, Strum SB, et al.: Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. J Urol 2006, 175:1673-1678.
60. •• Aus G: Current status of HIFU and cryotherapy in prostate cancer: a review. Eur Urol 2006, 50:927-934. This reviews a comprehensive MEDLINE search for all articles discussing both HIFU and cryosurgery as the primary treatment for patients with prostate cancer.
61. Smith JA Jr, Herrell SD: Robotic-assisted laparoscopic prostatectomy: do minimally invasive approaches offer significant advantages? J Clin Oncol 2005, 23:8170-8175.
62. Wiygul JB, Evans BR, Peterson BL, et al.: Supplement use among men with prostate cancer. Urology 2005, 66:161-166.